Huiyu Pharma Announces 3 Products Likely to be Selected in National Drug Procurement Program
Huiyu Pharma announced on August 2nd that it participated in the 12th round of national centralized drug procurement organized by the National Joint Procurement Office for Drugs. According to the "Proposed Winning Results Announcement for the 12th National Centralized Drug Procurement with Volume-Based Purchasing" released on July 31, 2026, by the Shanghai Sunshine Pharmaceutical Procurement Network, three of the company's products are slated for selection. These products include Epirubicin Hydrochloride for Injection, Teicoplanin for Injection, and Calcium Folinate Injection. This participation signifies the company's engagement in a key government initiative aimed at controlling drug costs and improving access.
Huiyu Pharma's likely inclusion in the 12th national drug procurement round highlights the ongoing impact of centralized purchasing policies on the pharmaceutical market. These programs aim to reduce healthcare expenditures by leveraging bulk purchasing power, which can lead to significant price reductions for selected medications. For pharmaceutical companies, successful bids can secure substantial market share and predictable revenue streams, albeit at lower margins. Conversely, the intense competition and pricing pressures inherent in such tenders necessitate robust R&D and efficient manufacturing capabilities to maintain profitability. The long-term implications involve a dynamic where innovation must be balanced with cost-effectiveness to navigate evolving public health procurement strategies.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.